- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 238284, 9 pages
Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer
1Translational Research Group, University Hospital Zurich, 8091 Zurich, Switzerland
2Ovarian Cancer Group, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales and School of Women’s and Children’s Health Clinical School, University of New South Wales, Sydney, NSW 2052, Australia
3Mathematics Institute for Analysis and Applications (MATHAA), EPFL, 1015 Lausanne, Switzerland
4Gynecological Research Group, University Hospital Basel, 4031 Basel, Switzerland
5Institute of Clinical Pathology, University Hospital Zurich, 8091 Zurich, Switzerland
6Department of Gynecology, University Hospital Zurich, 8091 Zurich, Switzerland
Received 18 February 2013; Revised 8 May 2013; Accepted 30 May 2013
Academic Editor: David J. Yang
Copyright © 2013 Michelle Buehler et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- L. A. Ries, M. P. Eisner, C. L. Kosary, et al., Eds., SEER Cancer Statistics Review, 1975–2000, 2003.
- F. Bray, A. H. Loos, S. Tognazzo, and C. La Vecchia, “Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953–2000,” International Journal of Cancer, vol. 113, no. 6, pp. 977–990, 2005.
- P. J. Russel, S. J. Robboy, and M. C. Anderson, “Ovarian tumors: classification and clinical perspective,” in Pathology of the Female Reproductive Tract, S. J. Robboy, M. C. Anderson, and P. J. Russel, Eds., pp. 527–538, Churchill Livingstone, London, UK, 2002.
- R. C. Bast Jr., F. J. Xu, Y. H. Yu, S. Barnhill, Z. Zhang, and G. B. Mills, “CA 125: the past and the future,” International Journal of Biological Markers, vol. 13, no. 4, pp. 179–187, 1998.
- G. Russo, C. Zegar, and A. Giordano, “Advantages and limitations of microarray technology in human cancer,” Oncogene, vol. 22, no. 43, pp. 6497–6507, 2003.
- J. M. Lancaster, H. K. Dressman, J. P. Clarke et al., “Identification of genes associated with ovarian cancer metastasis using microarray expression analysis,” International Journal of Gynecological Cancer, vol. 16, no. 5, pp. 1733–1745, 2006.
- M. E. Schaner, D. T. Ross, G. Ciaravino et al., “Gene expression patterns in ovarian carcinomas,” Molecular Biology of the Cell, vol. 14, no. 11, pp. 4376–4386, 2003.
- D. R. Schwartz, S. L. R. Kardia, K. A. Shedden et al., “Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas,” Cancer Research, vol. 62, no. 16, pp. 4722–4729, 2002.
- H. K. Dressman, A. Berchuck, G. Chan et al., “An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer (Journal of Clinical Oncology (2007) 25 (517–525)),” Journal of Clinical Oncology, vol. 30, no. 6, p. 678, 2012.
- M. Hutterer, P. Knyazev, A. Abate et al., “Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme,” Clinical Cancer Research, vol. 14, no. 1, pp. 130–138, 2008.
- T. Sawabu, H. Seno, T. Kawashima et al., “Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway,” Molecular Carcinogenesis, vol. 46, no. 2, pp. 155–164, 2007.
- W. Sun, J. Fujimoto, and T. Tamaya, “Coexpression of Gas6/Axl in human ovarian cancers,” Oncology, vol. 66, no. 6, pp. 450–457, 2004.
- P. Bellosta, Q. Zhang, S. P. Goff, and C. Basilico, “Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation,” Oncogene, vol. 15, no. 20, pp. 2387–2397, 1997.
- T. Nakano, K. Higashino, N. Kikuchi et al., “Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca2+-mobilizing growth factors,” The Journal of Biological Chemistry, vol. 270, no. 11, pp. 5702–5705, 1995.
- Y. C. Fridell, J. Villa Jr., E. C. Attar, and E. T. Liu, “GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells,” The Journal of Biological Chemistry, vol. 273, no. 12, pp. 7123–7126, 1998.
- P. Wirapati, C. Sotiriou, S. Kunkel et al., “Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures,” Breast Cancer Research, vol. 10, no. 4, article R65, 2008.
- L. V. Hedges and I. Olkin, Statistical Methods for Meta-Analysis, Academic Press, Orlando, Fla, USA, 1985.
- L. Bellido-Martín and P. G. de Frutos, “Vitamin K-dependent actions of Gas6,” Vitamins and Hormones, vol. 78, pp. 185–209, 2008.
- S. Hafizi and B. Dahlbäck, “Gas6 and protein S: vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily,” FEBS Journal, vol. 273, no. 23, pp. 5231–5244, 2006.
- K. Nagata, K. Ohashi, T. Nakano et al., “Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases,” The Journal of Biological Chemistry, vol. 271, no. 47, pp. 30022–30027, 1996.
- R. J. Craven, L. Xu, T. M. Weiner et al., “Receptor tyrosine kinases expressed in metastatic colon cancer,” International Journal of Cancer, vol. 60, no. 6, pp. 791–797, 1995.
- T. Ito, M. Ito, S. Naito et al., “Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma,” Thyroid, vol. 9, no. 6, pp. 563–567, 1999.
- C. Gjerdrum, C. Tiron, T. Høiby et al., “Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 3, pp. 1124–1129, 2010.
- A. Gustafsson, D. Martuszewska, M. Johansson et al., “Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival,” Clinical Cancer Research, vol. 15, no. 14, pp. 4742–4749, 2009.
- E. B. Rankin, K. C. Fuh, T. E. Taylor et al., “AXL is an essential factor and therapeutic target for metastatic ovarian cancer,” Cancer Research, vol. 70, no. 19, pp. 7570–7579, 2010.
- C. C. Hong, J. D. Lay, J. S. Huang et al., “Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia,” Cancer Letters, vol. 268, no. 2, pp. 314–324, 2008.
- Y. Shiozawa, E. A. Pedersen, L. R. Patel et al., “GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche,” Neoplasia, vol. 12, no. 2, pp. 116–127, 2010.
- P. P. Sainaghi, L. Castello, L. Bergamasco, M. Galletti, P. Bellosta, and G. C. Avanzi, “Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor,” Journal of Cellular Physiology, vol. 204, no. 1, pp. 36–44, 2005.
- O. Mc Cormack, W. Y. Chung, P. Fitzpatrick et al., “Growth arrest-specific gene 6 expression in human breast cancer,” The British Journal of Cancer, vol. 98, no. 6, pp. 1141–1146, 2008.